In MBC patients receiving high-dose chemotherapy, high frequencies of mature CD14+HLA-DR+ monocytes, as well as specific subpopulations of CD8+ and CD4+ T lymphocytes, are associated with longer breast cancer-specific survival [27]. This evidence concerns the gene CD14 and breast carcinoma.